| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 61 | COMPOSITIONS CONTAINING COMBINATIONS OF BIOACTIVE MOLECULES DERIVED FROM MICROBIOTA FOR TREATMENT OF DISEASE | US15680629 | 2017-08-18 | US20180000921A1 | 2018-01-04 | Kenya Honda; Bernat Olle; Koji Atarashi; Takeshi Tanoue; Hiroshi Ohno; Shinji Fukuda; Koji Hase |
| Compositions consisting of bioactive molecules derived from the microbiota of a mammal are provided herein. When administered orally with a colonic delivery system, the compositions are useful for the prophylaxis and treatment of diseases, in particular inflammatory, autoimmune and infectious diseases. The compositions comprise combinations of small molecules and bacterial antigens formulated in colonic delivery systems. Use of the compositions results in any or all of: induction of immune tolerance; strengthening of the gut mucosal barrier integrity; reduction of inflammation; and amelioration of a disease state caused by inflammation, an autoimmune reaction or an infectious agent. | ||||||
| 62 | Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease | US14903377 | 2014-07-08 | US09764019B2 | 2017-09-19 | Kenya Honda; Bernat Olle; Koji Atarashi; Takeshi Tanoue; Hiroshi Ohno; Shinji Fukuda; Koji Hase |
| Compositions consisting of bioactive molecules derived from the microbiota of a mammal are provided herein. When administered orally with a colonic delivery system, the compositions are useful for the prophylaxis and treatment of diseases, in particular inflammatory, autoimmune and infectious diseases. The compositions comprise combinations of small molecules and bacterial antigens formulated in colonic delivery systems. Use of the compositions results in any or all of: induction of immune tolerance; strengthening of the gut mucosal barrier integrity; reduction of inflammation; and amelioration of a disease state caused by inflammation, an autoimmune reaction or an infectious agent. | ||||||
| 63 | Eukaryotic Cells with Artificial Endosymbionts for Multimodal Detection | US15594594 | 2017-05-13 | US20170246325A1 | 2017-08-31 | Caleb B. Bell, III; Alexey Bazarov |
| The present invention is directed generally to eukaryotic cells comprising single-celled organisms that are introduced into the eukaryotic cell through human intervention and which transfer to daughter cells of the eukaryotic cell, and methods of introducing such single-celled organisms into eukaryotic cells. The invention provides single-celled organisms that introduce a phenotype to eukaryotic cells that is maintained in daughter cells. The invention additionally provides eukaryotic cells containing magnetic bacteria. The invention further provides eukaryotic cells engineered with single-celled organisms to allow for multimodal observation of the eukaryotic cells. Each imaging method (or modality) allows the visualization of different aspects of anatomy and physiology, and combining these allows the imager to learn more about the subject being imaged. | ||||||
| 64 | Monoclonal antibodies capable of reacting with a plurality of influenza virus A subtypes | US14938101 | 2015-11-11 | US09587011B2 | 2017-03-07 | Roberto Burioni; Massimo Clementi |
| Monoclonal antibodies directed against the influenza A virus are described, which have the advantageous and unpredicted property of being able to bind a plurality of subtypes of the influenza A virus. One preferred embodiment is the antibody designated as Fab28, which displays a neutralizing activity against a plurality of subtypes of the influenza A virus. Anti-idiotype antibodies directed against the monoclonal antibodies of the invention, immunogenic or vaccine compositions comprising the monoclonal antibodies of the invention are also described, as well as therapeutic, prophylactic and diagnostic applications for the monoclonal antibodies of the invention. The monoclonal antibodies of the invention can also be used for testing antibody preparations to be used as vaccines. | ||||||
| 65 | Eukaryotic Cells with Artificial Endosymbionts for Multimodal Detection | US15263144 | 2016-09-12 | US20160376670A1 | 2016-12-29 | Caleb B. Bell, III; Alexey Bazarov |
| The present invention is directed generally to eukaryotic cells comprising single-celled organisms that are introduced into the eukaryotic cell through human intervention and which transfer to daughter cells of the eukaryotic cell, and methods of introducing such single-celled organisms into eukaryotic cells. The invention provides single-celled organisms that introduce a phenotype to eukaryotic cells that is maintained in daughter cells. The invention additionally provides eukaryotic cells containing magnetic bacteria. The invention further provides eukaryotic cells engineered with single-celled organisms to allow for multimodal observation of the eukaryotic cells. Each imaging method (or modality) allows the visualization of different aspects of anatomy and physiology, and combining these allows the imager to learn more about the subject being imaged. | ||||||
| 66 | METHOD FOR REDUCING ADHESION OF MICROORGANISMS TO FABRICS | US15104710 | 2014-12-18 | US20160319480A1 | 2016-11-03 | Heinz KATZENMEIER; Peter STUTTE; Sabrina SCHMIDT-EMRICH; Linda THOENY-MEYER; Qun Ren ZULIAN |
| The present invention relates to a method for finishing fibers and/or fabrics, the intention being to reduce the adhesion of microorganisms, especially of bacteria and/or yeasts, to the fibers and/or fabrics. The method involves applying a composition ZS comprising selected hydrophilic silane derivatives to the fibers and/or fabrics. The invention further relates to a method for the quantitative determination of the adhesion of microorganisms to fibers and/or fabrics. | ||||||
| 67 | Predictive Biomarker for Cancer Therapy | US14891869 | 2014-05-15 | US20160115479A1 | 2016-04-28 | Matthias Schroff; Manuel Schmidt; Kerstin Kapp; Burghardt Wittig |
| The present invention relates generally to the identification of patients suffering from cancer whether they will respond to specific therapies. More particularly the invention relates to a method and means for identifying responder to a therapy TLR-9 agonists. | ||||||
| 68 | Antibodies directed against influenza | US14350632 | 2012-10-18 | US09321829B2 | 2016-04-26 | Rafi Ahmed; Jens Wrammert; Patrick C. Wilson |
| Antibodies that specifically bind influenza virus hemagglutinin A (HA), and antigen binding fragments thereof are disclosed herein. In several embodiments, these antibodies are broadly neutralizing. Nucleic acids encoding these monoclonal antibodies, vectors including these nucleic acids, and host cells transformed with these vectors are also disclosed. Compositions are disclosed that include these antibodies, antigen binding fragments, nucleic acids, vectors and host cells. Method of using these antibodies, and antigen binding fragments, nucleic acids, vectors and host cells, such as for diagnosis and treatment of an influenza virus infection are also provided. | ||||||
| 69 | Quantitative multiplex detection of pathogen biomarkers | US14317378 | 2014-06-27 | US09255923B2 | 2016-02-09 | Harshini Mukundan; Hongzhi Xie; Basil I. Swanson; Jennifer Martinez; Wynne K. Grace |
| The present invention addresses the simultaneous detection and quantitative measurement of multiple biomolecules, e.g., pathogen biomarkers through either a sandwich assay approach or a lipid insertion approach. The invention can further employ a multichannel, structure with multi-sensor elements per channel. | ||||||
| 70 | Eukaryotic Cells with Artificial Endosymbionts for Multimodal Detection | US14689987 | 2015-04-17 | US20150275182A1 | 2015-10-01 | Caleb B. Bell, III; Alexey Bazarov |
| The present invention is directed generally to eukaryotic cells comprising single-celled organisms that are introduced into the eukaryotic cell through human intervention and which transfer to daughter cells of the eukaryotic cell, and methods of introducing such single-celled organisms into eukaryotic cells. The invention provides single-celled organisms that introduce a phenotype to eukaryotic cells that is maintained in daughter cells. The invention additionally provides eukaryotic cells containing magnetic bacteria. The invention further provides eukaryotic cells engineered with single-celled organisms to allow for multimodal observation of the eukaryotic cells. Each imaging method (or modality) allows the visualization of different aspects of anatomy and physiology, and combining these allows the imager to learn more about the subject being imaged. | ||||||
| 71 | Eukaryotic cells with artificial endosymbionts for multimodal detection | US14332373 | 2014-07-15 | US09023612B2 | 2015-05-05 | Caleb B. Bell, III; Alexey Bazarov |
| The present invention is directed generally to eukaryotic cells comprising single-celled organisms that are introduced into the eukaryotic cell through human intervention and which transfer to daughter cells of the eukaryotic cell, and methods of introducing such single-celled organisms into eukaryotic cells. The invention provides single-celled organisms that introduce a phenotype to eukaryotic cells that is maintained in daughter cells. The invention additionally provides eukaryotic cells containing magnetic bacteria. The invention further provides eukaryotic cells engineered with single-celled organisms to allow for multimodal observation of the eukaryotic cells. Each imaging method (or modality) allows the visualization of different aspects of anatomy and physiology, and combining these allows the imager to learn more about the subject being imaged. | ||||||
| 72 | ANTIBODIES DIRECTED AGAINST INFLUENZA | US14350632 | 2012-10-18 | US20140348851A1 | 2014-11-27 | Rafi Ahmed; Jens Wrammert; Patrick C. Wilson |
| Antibodies that specifically bind influenza virus hemagglutinin A (HA), and antigen binding fragments thereof are disclosed herein. In several embodiments, these antibodies are broadly neutralizing. Nucleic acids encoding these monoclonal antibodies, vectors including these nucleic acids, and host cells transformed with these vectors are also disclosed. Compositions are disclosed that include these antibodies, antigen binding fragments, nucleic acids, vectors and host cells. Method of using these antibodies, and antigen binding fragments, nucleic acids, vectors and host cells, such as for diagnosis and treatment of an influenza virus infection are also provided. | ||||||
| 73 | Method and Device for Combined Detection of Viral and Bacterial Infections | US13790125 | 2013-03-08 | US20130196310A1 | 2013-08-01 | Robert P. Sambursky; Robert W. VanDine; Uma Mahesh Babu; Peter Condon |
| A lateral flow assay is capable of detecting and differentiating viral and bacterial infections. A combined point of care diagnostic device tests markers for viral infection and markers for bacterial infection, to effectively assist in the rapid differentiation of viral and bacterial infections. In some preferred embodiments, bimodal methods and devices determine if an infection is bacterial and/or viral. A dual use two strip sample analysis device includes a first lateral flow chromatographic test strip to detect MxA and a low level of C-reactive protein and a second lateral flow chromatographic test strip to detect high levels of C-reactive protein. In some preferred embodiments, the sample is a fingerstick blood sample. | ||||||
| 74 | Quantitative multiplex detection of pathogen biomarkers | US12924929 | 2010-10-08 | US20110117585A1 | 2011-05-19 | Harshini Mukundan; Hongzhi Xie; Basil I. Swanson; Jennifer Martinez; Wynne K. Grace |
| The present invention addresses the simultaneous detection and quantitative measurement of multiple biomolecules, e.g., pathogen biomarkers through either a sandwich assay approach or a lipid insertion approach. The invention can further employ a multichannel, structure with multi-sensor elements per channel. | ||||||
| 75 | MONOCLONAL ANTIBODIES CAPABLE OF REACTING WITH A PLURALITY OF INFLUENZA VIRUS A SUBTYPES | US12922850 | 2009-03-16 | US20110014187A1 | 2011-01-20 | Roberto Burioni; Massimo Clementi |
| Monoclonal antibodies directed against the influenza A virus are described, which have the advantageous and unpredicted property of being able to bind a plurality of subtypes of the influenza A virus. One preferred embodiment is the antibody designated as Fab28, which displays a neutralizing activity against a plurality of subtypes of the influenza A virus. Anti-idiotype antibodies directed against the monoclonal antibodies of the invention, immunogenic or vaccine compositions comprising the monoclonal antibodies of the invention are also described, as well as therapeutic, prophylactic and diagnostic applications for the monoclonal antibodies of the invention. The monoclonal antibodies of the invention can also be used for testing antibody preparations to be used as vaccines. | ||||||
| 76 | SDRD protein from Staphylococcus aureus and diagnostic kits including same | US12546289 | 2009-08-24 | US07834151B2 | 2010-11-16 | Joseph M. Patti; Timothy J. Foster; Elisabet Josefsson; Deidre Ni Eidhin; Magnus A. O. Hook; Samuel E. Perkins |
| An isolated extracellular matrix-binding protein, designated as SdrD and its corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of S. aureus to wounds or biomaterials. | ||||||
| 77 | SdrC protein from Staphylococcus aureus and diagnostic kits including same | US12546268 | 2009-08-24 | US07816494B2 | 2010-10-19 | Joseph M. Patti; Timothy J. Foster; Elizabet Joseffson; Deidre Ni Eidhin; Magnus A. O. Hook; Samuel E. Perkins |
| An isolated extracellular matrix-binding protein, designated as SdrC and its corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of S. aureus to wounds or biomaterials. | ||||||
| 78 | USE OF COMMON GAMMA CHAIN CYTOKINES FOR THE VISUALIZATION, ISOLATION AND GENETIC MODIFICATION OF MEMORY T LYMPHOCYTES | US12063373 | 2006-08-03 | US20100035282A1 | 2010-02-11 | Maria Chiara Bonini; Attilio Bondanza; Anna Mondino; Stefano Caserta |
| It is described in vitro methods for expanding, detecting or isolating rare populations of antigen specific memory T cells. It is also described an in vitro method for obtaining a genetically modified memory T cell population. Uses of cells so obtained are also disclosed. | ||||||
| 79 | Toxoplasma gondii Oocyst Protein | US12436596 | 2009-05-06 | US20090215696A1 | 2009-08-27 | Dolores E. Hill; Dante S. Zarlenga; Cathleen Coss; Jitender P. Dubey |
| Recombinant proteins have been developed for the detection of Toxoplasma gondii oocyst proteins for example in biological fluids. Isolated DNA sequences which encode these proteins have also been developed. The DNA sequences may be inserted into recombinant DNA molecules such as cloning vectors or expression vectors for the transformation of cells and the production of the proteins. | ||||||
| 80 | Extracellular matrix-binding proteins from Staphylococcus aureus | US10744616 | 2003-12-24 | US20050026170A1 | 2005-02-03 | Joseph Patti; Timothy Foster; Elisabet Josefsson; Deidre Eidhin; Magnus Hook; Samuel Perkins |
| Isolated extracellular matrix-binding proteins, designated ClfB, SdrC, SdrD and SdrE, and their corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of S. aureus to wounds or biomaterials. ClfB is a cell-wall associated protein having a predicted molecular weight of approximately 88 kDa and an apparent molecular weight of approximately 124 kDa, which binds both soluble and immobilized fibrinogen. ClfB binds both the alpha and beta chains of fibrinogen and acts as a clumping factor. SdrC, SdrD and SdrE are cell-wall associated proteins that exhibit cation-dependent ligand binding to the extracellular matrix. It has been discovered that in the A region of SdrC, SdrD, SdrE, ClfA and ClfB, there is a highly conserved amino acid sequence that can be used to derive a consensus motif of TYTFTDYVD. | ||||||
QQ群二维码
意见反馈
意见反馈